Rohto Pharmaceutical Co.,Ltd. (FRA:UC1)

Market Cap	2.82B -9.6%
Revenue (ttm)	1.82B +13.6%
Net Income	187.63M +16.8%
EPS	0.81 +14.9%
Shares Out	n/a
PE Ratio	15.04
Forward PE	n/a
Dividend	0.24 (1.96%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Average Volume	n/a
Open	12.60
Previous Close	12.30
Day's Range	12.60 - 12.60
52-Week Range	11.60 - 14.80
Beta	n/a
RSI	38.04
Earnings Date	May 12, 2026

About Rohto Pharmaceutical

Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin, lip balms, sunscreens, functional cosmetics, etc.; medicine for internal use, such as digestive and herbal medicines; regenerative medicines; OTC pharmaceutical products, including ophthalmic, dermatologi...

• Industry: Perfumes, Cosmetics, and Other Toilet Preparations
• Founded: 1899
• Employees: 9,144
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: UC1

Financial Performance

In fiscal year 2025, Rohto Pharmaceutical's revenue was 308.63 billion, an increase of 13.95% compared to the previous year's 270.84 billion. Earnings were 31.01 billion, an increase of 0.23%.

Financial numbers in JPY